Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers

Blood

Volumn 103, Issue 1, 2004, Pages 325-332

  Zeng, Weihua ^a   Chen, Guibin ^a   Kajigaya, Sachiko ^a   Nunez, Olga ^a   Charrow, Alexandra ^a   Billings, Eric M ^a   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; OLIGONUCLEOTIDE; RNA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW CELL; BONE MARROW DEPRESSION; CELL CYCLE; CELL PROLIFERATION; CHEMOKINE SIGNAL TRANSDUCER GENE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE SIGNAL TRANSDUCER GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE GENE; MALE; PRIORITY JOURNAL; STRESS RESPONSE GENE; TARGET CELL;

EID: 0346966820     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-02-0490     Document Type: Article

References (39)

1. Young NS. Acquired aplastic anemia. Ann Intern Med. 2002;136:534-546.
2. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H; German Aplastic Anemia Study Group. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236-1242.
3. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130-1135.
4. Bacigalupo A, Bruno B, Saracco P, et al. Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (G ITMO). Blood. 2000;95:1931-1934.
5. Maciejewski JP, Sloand EM, Nunez O, Boss C, Young NS. Recombinant humanized anti-IL-21 receptor antibody (Daclizumab) produces responses in patients with moderate aplastic anemia. Blood. 2003;102:3584-3586.
6. Geissler K, Kabrna E, Kollars M, et al. Interleukin-10 inhibits in vitro hematopoietic suppression and production of interferon-gamma and tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with aplastic anemia. Hematol J. 2002;3:206-213.
7. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood. 2002;100:1185-1191.
8. Nakao S, Yamaguchi M, Shiobara S, et al. Interferon-gamma gene expression in unstimulated bone marrow mononuclear cells predicts a good response to cyclosporine therapy in aplastic anemia. Blood. 1992;79:2532-2535.
9. Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol. 2001;115:1023-1031.
10. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V beta CDR3 spectratyping and flow cytometry. Blood. 2002;100:178-183.
11. Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood. 2002;99:3668-3675.
12. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest. 2001;108:765-773.
13. Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999;93:3008-3016.
14. Nakao S, Takami A, Takamatsu H, et al. Isolation of a T-cell clone showing HLA-DRB1 *0405-restricted cytotoxicity for hematopoietic cells in a patient with aplastic anemia. Blood. 1997;89:3691-3699.
15. Pfister O, Chklovskaia E, Jansen W, et al. Chronic overexpression of membrane-bound fit3 ligand by T lymphocytes in severe aplastic anaemia. Br J Haematol. 2000;109:211-220.
16. Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 1995;86:4091-4096.
17. Fujimaki S, Harigae H, Sugawara T, Takasawa N, Sasaki T, Kaku M. Decreased expression of transcription factor GATA-2 in haematopoietic stem cells in patients with aplastic anaemia. Br J Haematol. 2001;113:52-57.
18. Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of gene expression in human CD34(+) stem/progenitor cells. Proc Natl Acad Sci U S A. 2001;98:13966-13971.
19. Steidl U, Kronenwett R, Rohr UP, et al. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood. 2002;99:2037-2044.
20. Lock C, Hermans G, Pedotti R, et al. Genemicroarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Mod. 2002;8:500-508.
21. Kaufman DW, Kelly JP, Jurgeion JM, et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol Suppl, 1996;60:23-30.
22. Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood. 1979;53:504-514.
23. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-408.
24. Tan FL, Moravec CS, Li J, et al. The gene expression fingerprint of human heart failure. Proc Natl Acad Sci U S A. 2002;99:11387-11392.
25. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365-1372.
26. Dieude P, Petit E, Cailleau-Moindrault S, et al. Association between tumor necrosis factor receptor II and familial, but not sporadic, rheumatoid arthritis: evidence for genetic heterogeneity. Arthritis Rheum. 2002;46:2039-2044.
27. Apostolou I, Hao Z, Rajewsky K, Von Boehmer H. Effective destruction of Fas-deficient insulin-producing β cells in type 1 diabetes. J Exp Med. 2003;198:1103-1106.
28. Takekawa M, Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell. 1998;95:521-530.
29. Mita H, Tsutsui J, Takekawa M, Witten EA, Saito H. Regulation of MTK1/MEKK4 kinase activity by its N-terminal autoinhibitory domain and GADD45 binding. Mol Cell Biol. 2002;22:4544-4555.
30. Curran JE, Weinstein SR, Griffiths LR. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett. 2002;188:103-107.
31. Geissler K, Kabrna E, Kollars M, et al. Interleukin-10 inhibits in vitro hematopoietic suppression and production of interferon-gamma and tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with aplastic anemia. Hematol J. 2002;3:206-213.
32. Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
33. Hitchon C, Wong K, Ma G, Reed J, Lyttle D, EI Gabalawy H. Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum. 2002;46:2587-2597.
34. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinfiammatory cytokines, and autoimmunity. Ann N Y Acad Sci. 2002;966:290-303.
35. Ewen ME. Where the cell cycle and histones meet. Genes Dev. 2000;14:2265-2270.
36. Reed SI. Control of the G1/S transition. Cancer Surv. 1997;29:7-23.
37. Ravitz MJ, Wenner CE. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res. 1997;71:165-207.
38. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501-1512.
39. von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68-72.